Camrelizumab plus apatinib shows promise in pretreated biliary tract cancer

A regimen of camrelizumab plus apatinib appears to be safe and effective in patients with pretreated biliary tract cancer, according to a study.

In this prospective, non-randomized, open-label trial, patients with biliary tract cancer who have received previously undergone treatments, received apatinib orally and camrelizumab intravenously every 3 weeks until disease progression or intolerable toxicity occurred.

Of the 21 patients who had efficacy evaluations, none achieved complete response and 19% achieved partial response, while 11 patients had stable disease with a disease control rate of 71.4%. The median overall survival and the median progression-free survival was 13.1 months and 4.4 months, respectively.

Grade 3 of 4 adverse events occurred in 63.6% of patients. There were no treatment related deaths.

Reference
Wang D, Yang X, Long J, et al. The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: A prospective clinical study. Front Oncol. 2021;11:646979. DOI: 10.3389/fonc.2021.646979. PMID: 33912461; PMCID: PMC8071846.